Health Trials

About this trial

The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical \[F-18\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \[F-18\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with \[F-18\]DPA-714-PET/MRI.

Eligibility criteria

Qualifiers

18 to 65 years of age

Healthy volunteer OR Clinical diagnosis of Multiple Sclerosis (MS) OR Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome

Disqualifiers

Contraindication to MRI

Pregnancy

Lactation

Individuals who are unable to participate in the imaging portion due to severity of their medical condition

Trial design

Treatments tested in this trial

  • DPA-714 PET/MRI

Treatment groups

120 Participants
are divided into 4 treatment groups

Locations

1
University of Alabama at Birmingham Medical Center35294, BirminghamAlabama, United States

Sponsors and collaborators

University of Alabama at Birmingham

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Source ClinicalTrials.gov